MEDX Xelerator01.05.21
MEDX Xelerator, an Israel-based medical device and digital health incubator, has announced approval of its latest “X Lab” project focused on treating peripheral venous disease (PVD). The newly formed company, VeinWay, will be headed by experienced biomedical engineer and freshman entrepreneur Jordan Pollack.
VeinWay recently received a grant of more than $35,000 from The Ideation (Tnufa) Incentive Program of The Israel Innovation Authority. The goal of the grant is to support the company in reaching proof of concept and business feasibility.
MEDX Xelerator’s X Lab program was established to cultivate promising innovation at its earliest stage, supporting and helping inventors and entrepreneurs cultivate their ideas addressing complex unmet clinical needs. By providing resources, industry expertise and wide-spread networking capabilities, MEDX supports its X Lab entrepreneurs in developing a proof-of-concept, and then, if a proof of concept is demonstrated, advancing these early stage startups to enter the formal incubator program.
“It’s a great privilege to be inducted into the X Lab program and gain the full support and guidance of the extended MEDX team,” said Jordan Pollack, X Lab Entrepreneur in Residence and CEO of VeinWay. “I am excited to collaborate with MEDX’s experienced and well-connected leadership to leverage my peripheral vasculature expertise and together, to provide the industry with much-needed innovation to improve care for patients with PVD.”
Pollack has spent his career building his engineering experience within the medical device field, having held multiple positions in established, globally traded companies including Boston Scientific Corp. and InspireMD. Pollack was also president and CEO of his own startup, LiveSAVR Solutions, which developed a smart guidewire for accurate placement of transcatheter aortic valves. Pollack holds master’s and bachelor’s degrees in biomedical engineering from the University of Michigan.
“Our relationship with Jordan stems back to a joint project with Boston Scientific, where we first noticed his extensive knowledge of the peripheral venous industry and entrepreneurial spirit,” said Shai Policker, CEO of MEDX Xelerator. “Following his recent immigration to Israel, we are delighted to play a role in guiding and nurturing his growth and development within this field, and are happy to assist in Jordan’s goal of elevating the standard of care for PVD management.”
VeinWay recently received a grant of more than $35,000 from The Ideation (Tnufa) Incentive Program of The Israel Innovation Authority. The goal of the grant is to support the company in reaching proof of concept and business feasibility.
MEDX Xelerator’s X Lab program was established to cultivate promising innovation at its earliest stage, supporting and helping inventors and entrepreneurs cultivate their ideas addressing complex unmet clinical needs. By providing resources, industry expertise and wide-spread networking capabilities, MEDX supports its X Lab entrepreneurs in developing a proof-of-concept, and then, if a proof of concept is demonstrated, advancing these early stage startups to enter the formal incubator program.
“It’s a great privilege to be inducted into the X Lab program and gain the full support and guidance of the extended MEDX team,” said Jordan Pollack, X Lab Entrepreneur in Residence and CEO of VeinWay. “I am excited to collaborate with MEDX’s experienced and well-connected leadership to leverage my peripheral vasculature expertise and together, to provide the industry with much-needed innovation to improve care for patients with PVD.”
Pollack has spent his career building his engineering experience within the medical device field, having held multiple positions in established, globally traded companies including Boston Scientific Corp. and InspireMD. Pollack was also president and CEO of his own startup, LiveSAVR Solutions, which developed a smart guidewire for accurate placement of transcatheter aortic valves. Pollack holds master’s and bachelor’s degrees in biomedical engineering from the University of Michigan.
“Our relationship with Jordan stems back to a joint project with Boston Scientific, where we first noticed his extensive knowledge of the peripheral venous industry and entrepreneurial spirit,” said Shai Policker, CEO of MEDX Xelerator. “Following his recent immigration to Israel, we are delighted to play a role in guiding and nurturing his growth and development within this field, and are happy to assist in Jordan’s goal of elevating the standard of care for PVD management.”
